biostudies-literatureJacquet-Guibon SAgence Nationale de la Recherchee0191796https://www.ebi.ac.uk/biostudies/studies/S-EPMC5844532biostudies-literatureUnknown13(3)A randomized controlled trial was performed on racing horses, to evaluate the efficacy of a new class of therapeutic agents in regenerative medicine-ReGeneraTing Agents® (RGTA®), to treat tendinopathies. Preliminary uncontrolled studies on tendon healing in racing horses with RGTA® (OTR4131)-Equitend® showed encouraging results, justifying performing a randomized, controlled, multicenter study with a two-year racing performance follow up. The objective of this study was to evaluate the effect of Equitend® versus placebo on acute superficial digital flexor tendonitis in racing French Standardbred Trotters (ST). Twenty-two ST were randomly and blindly assigned to receive with a ratio of 2 to 1, a single Equitend® (n = 14) or placebo (n = 8) intralesional injection under ultrasonographic guidPloS oneRandomized controlled trial demonstrates the benefit of RGTA® based matrix therapy to treat tendinopathies in racing horses.PMC5844532ANR-08-BIOT-0021Barritault DJacquet-Guibon SCrevier-Denoix NChiappini FSineriz FCoudry VDenoix JMLeroy SDupays AGfalseRandomized controlled trial demonstrates the benefit of RGTA® based matrix therapy to treat tendinopathies in racing horses.A randomized controlled trial was performed on racing horses, to evaluate the efficacy of a new class of therapeutic agents in regenerative medicine-ReGeneraTing Agents® (RGTA®), to treat tendinopathies. Preliminary uncontrolled studies on tendon healing in racing horses with RGTA® (OTR4131)-Equitend® showed encouraging results, justifying performing a randomized, controlled, multicenter study with a two-year racing performance follow up. The objective of this study was to evaluate the effect of Equitend® versus placebo on acute superficial digital flexor tendonitis in racing French Standardbred Trotters (ST). Twenty-two ST were randomly and blindly assigned to receive with a ratio of 2 to 1, a single Equitend® (n = 14) or placebo (n = 8) intralesional injection under ultrasonographic guid2018-01-01T00:00:00Z20182025-05-29T22:10:46.347Z2025-05-29T22:10:46.347ZS-EPMC58445322952256410.1371/journal.pone.0191796